Literature DB >> 1693569

Estrogen increases galanin immunoreactivity in hyperplastic prolactin-secreting cells in Fisher 344 rats.

D W Hsu1, M el-Azouzi, P M Black, W W Chin, E T Hedley-Whyte, L M Kaplan.   

Abstract

Galanin is a widely distributed regulatory peptide which modulates the pituitary secretion of PRL and GH. Estrogen administration strongly stimulates galanin gene expression in the rat anterior pituitary. In adult female Fischer 344 rats, estrogen also induces hyperplasia of lactotropes. We used immunocytochemical analysis to assess the effects of estrogen on galanin-like immunoreactivity (Gal-IR) in the rat pituitary and hypothalamus during sc diethylstilbestrol (DES) implantation and after its removal at 30 days. In the anterior pituitary, DES implantation increased the portion of Gal-IR-containing cells from less than 2% in the control rats to 18.3% after 3 days of DES and 36% after 30 days. These changes paralleled the lactotrope hyperplasia exhibited in response to DES exposure. Ten and 30 days after removal of the DES capsules, the percentage of Gal-IR-containing cells in the anterior pituitary decreased to 6.3% and 1.5%, respectively. Colocalization studies revealed that Gal-IR-containing cells were predominantly lactotropes. Immunoelectron microscopy demonstrated that Gal-IR was concentrated in the Golgi region of these hyperplastic lactotropes and suggests that little of the synthesized galanin is secreted. The distribution of Gal-IR in the hypothalamus, median eminence, and neurohypophysis was unaffected by DES treatment. These data demonstrate that galanin is synthesized by hyperplastic pituitary lactotropes of Fischer 344 rats and that peptide accumulation is dependent on the presence of circulating estrogens. In contrast, neuronal galanin synthesis in the hypothalamus does not appear to be regulated by estrogen.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1693569     DOI: 10.1210/endo-126-6-3159

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

1.  Galanin-like immunoreactivity is increased in the brain of estradiol- and methyltestosterone-treated eels.

Authors:  M Olivereau; J Olivereau
Journal:  Histochemistry       Date:  1991

2.  Corticotroph (Basophil) invasion of the pars nervosa in the human pituitary: Localization of proopiomelanocortin peptides, galanin and peptidylglycine α-amidating monooxygenase-like immunoreactivities.

Authors:  Ricardo V Lloyd; Constance J D'Amato; Michelle T Thiny; Long Jin; Samuel P Hicks; William F Chandler
Journal:  Endocr Pathol       Date:  1993-06       Impact factor: 3.943

Review 3.  Estrogen action in the regulation of cell proliferation, cell survival, and tumorigenesis in the rat anterior pituitary gland.

Authors:  T J Spady; R D McComb; J D Shull
Journal:  Endocrine       Date:  1999-12       Impact factor: 3.633

4.  Coexpression of galanin and adrenocorticotropic hormone in human pituitary and pituitary adenomas.

Authors:  D W Hsu; S C Hooi; E T Hedley-Whyte; R M Strauss; L M Kaplan
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

5.  Modulation of galanin and neuromedin U-like immunoreactivity in rat corticotropes after alteration of endocrine status.

Authors:  V Cimini; S Van Noorden; C M Timson; J M Polak
Journal:  Cell Tissue Res       Date:  1993-04       Impact factor: 5.249

6.  Rat strain specific attenuation of estrogen action in the anterior pituitary gland by dietary energy restriction.

Authors:  Djuana M E Harvell; Linda K Buckles; Karen A Gould; Karen L Pennington; Rodney D McComb; James D Shull
Journal:  Endocrine       Date:  2003-07       Impact factor: 3.633

Review 7.  Potential of gene therapy for the treatment of pituitary tumors.

Authors:  R G Goya; D K Sarkar; O A Brown; C B Hereñú
Journal:  Curr Gene Ther       Date:  2004-03       Impact factor: 4.391

Review 8.  The Galaninergic System: A Target for Cancer Treatment.

Authors:  Manuel Lisardo Sánchez; Rafael Coveñas
Journal:  Cancers (Basel)       Date:  2022-08-01       Impact factor: 6.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.